Apogee Therapeutics (APGE) Long-Term Deferred Tax (2023)

Apogee Therapeutics (APGE) reported Long-Term Deferred Tax of $30.8 million for Q4 2023.

Apogee Therapeutics (APGE) Long-Term Deferred Tax (2023) Analysis & Trends

Apogee Therapeutics (APGE) has 1 years of Long-Term Deferred Tax data on file, last reported at $30.8 million in Q4 2023.

Long-Term Deferred Tax for Q4 2023 came in at $30.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $30.8 million (changed N/A YoY), and the FY2023 annual result was $30.8 million, changed N/A from the prior year.
Long-Term Deferred Tax held at $30.8 million in Q4 2023 per APGE's latest filing.
Over five years, Long-Term Deferred Tax peaked at $30.8 million in Q4 2023 and troughed at $30.8 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Apogee Therapeutics	6.29 Bn	5.23 Bn	-

Download Data

Date	Value
Dec 31, 2023	30.75 Mn